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ABSTRACT
Objective: Because epidemiological data on circulating HIV subtypes among HIV-positive patients 
in the state of Paraná were not known until now, the aims of this study were to describe the genetic 
diversity profi le of HIV-1 in treated patients in Paraná, Brazil, and report the differences in protease 
(PR) and reverse transcriptase (RT) mutations in HIV-1 subtypes. Patients and methods: A cross-
sectional study was conducted from 2003 to 2006. Plasma viral RNA of 389 patients was extracted 
and PR and RT genes were polymerase chain reaction-amplifi ed and sequenced. Sequences were 
subtyped and examined for antiretroviral resistance mutations. Data on gender of patient harboring 
the viruses and past history of antiretroviral treatment were also collected. Results: Most viruses were 
either subtype B (61.44%) or subtype C (20.57%). Subtype C and F were more frequent in women 
(p < 0.00). The prevalence of subtypes was similar over the years studied. The most frequent RT 
mutations in all subtypes were M184V and mutations at codons 215, 41, 103, 67, 219, and 190. Muta-
tions 41L, 210W, 215YF, and 74V were signifi cantly more prevalent on subtype B, and the mutation 
106M was signifi cantly more prevalent on subtype C. The most frequent major PI mutations in all 
subtypes occurred at codons 46, 82, and 90. PR mutations 32I, 46I, and 84V were signifi cantly more 
prevalent on subtype B. The minor PI mutations on codons 36, 93, and 63 were more prevalent on 
subtypes F, C, and B, respectively. Conclusion: We concluded that the predominant strain of HIV-1 
in Paraná is subtype B, followed by subtype C. Some mutations at PR and TR had subtype predomi-
nance in accordance with other authors’ report.
Keywords: HIV-1 subtypes, genotype, antiretroviral, drug experienced patients.
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INTRODUCTION
HIV is classifi ed in two genetically diverse types: 
HIV- 1 and HIV-2. Three groups of HIV- 1 are 
described: group M (“main”), O (“outlier”), 
and N (“neither, non-M–non-O, or new”).1 
Nine subtypes (A, B, C, D, F, G, H, J, and K) 
and at least 43 recombinant intersubtypes oc-
curring when an individual is infected with two 
separate strains of the virus, the “circulating re-
combinant forms”, are described in HIV-1 pan-
demic group M.2-5
The description of different subtypes was 
initially based on genomic sequences called 
“env”, but can be based on every region of viral 
genome, including “pol” in which protease (PR) 
and reverse transcriptase (RT) are encoded.6
Only 12% of HIV-1 infection worldwide is 
from subtype B, but in developed countries of 
Western Europe and the United States it occurs 
in more than 90% of cases.7 Subtype C of HIV-1 
is currently the most prevalent virus in more than 
50% of HIV infections worldwide, with increased 
prevalence in countries with high HIV infection 
rates among heterosexuals, such as those of sub-
Saharan Africa, India, and China. Recombinant 
forms account for 18% of the global infections.8
In Brazil, although subtype B is still more 
common nationwide, subtype C has been in-
creasingly prevalent in the south.9-13 Brindeiro et 
al. (2003), described the following proportions 
of subtypes in PR and RT: subtype C in 22.8% 
and 29.5%, subtype B in 64.9% and 62.5%, and 
subtype F in 11.8% and 8% of cases.14 The fi rst 
reports of recombination in our country were 
of CRFs representing mosaics of subtypes B and 
F.15 Most studies conducted in Brazil to evaluate 
HIV diversity have been carried out using sam-
ples from the Southeast region16-18 and from the 
southern state of Rio Grande do Sul,9,12 and so far 
there is no information regarding circulation of 
HIV subtypes in Paraná in recent years. Ferreira 
et al. reported the prevalence of HIV-1 subtypes 
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in newly infected patients in Curitiba, Paraná,13 but the HIV 
diversity ib the state in the last years has not been reported.
Regarding international data on PR and RT mutation dis-
tributions in non-B subtypes (A, C, D, F, G, AE, AG) compared 
to subtype B, 80% of mutations related to antiretroviral (ARV) 
resistance in subtype B also confer resistance in other subtypes. 
Among resistance mutations in non-B subtypes, 91% were also 
present in B subtypes.19
The present study aims to describe the genetic diversity of 
HIV-1 in Paraná. The distribution of virus subtypes over the 
years is described. The genotypic resistance of subtypes to treat-
ment is observed, based on the proportion of PR and RT muta-
tions, and differences of these mutations in HIV-1 subtypes are 
reported.
 
MATERIAL AND METHODS
This study was approved by the Ethics Committee of Clinic 
Hospital of Federal University of Paraná (UFPR) and by the 
Laboratory Division of Brazilian AIDS Program (PN-DST/
AIDS) of Brazilian Ministry of Health (MH).
HIV-1 genotypes of adults on ARV treatment failure in 
Paraná, Brazil, tested from 2003 to 2006 were selected for 
this study. The sources were genotypes of private patients 
and local genotype results from the National Genotyping 
Network (RENAGENO). Informed consent was signed by 
all patients before sample collection.
All patients were exposed to at least two ARV including: 
nucleoside analog reverse transcriptase inhibitors (NRTIs), 
non-nucleoside analog reverse transcriptase inhibitors 
(NNRTIs), and protease inhibitors (PIs). Patients were ex-
cluded if ART data were missing or incomplete.
HIV-1 genomic region analyzed was POL, specifi cally the 
codons of PR and RT. Genotypic sequencing was performed 
using commercially available assays. The reports from RE-
NAGENO where performed by ViroSeq HIV-1 Genotype 
System® from Celera Diagnostics (Applied Byosystems). 
The reports of private patients were performed by one of 
the following assays: GenoSure® (by LabCorp), vircoTYPE 
HIV-1® (by VIRCO) and GeneSeq® (by Monogram, for-
merly ViroLogic Inc.).
A subtyping tool by sequence was used based on RE-
NAGENO recommendations, and phylogenetic analysis of 
partial POL sequences was not performed. 
Mutations deﬁ nition
Mutations associated with reduced antiretroviral drug sus-
ceptibility analyzed in this study were based on data reported 
by the International AIDS Society – USA Panel Guidelines 
reported from 2000 to 2008.20
Database construction
Data collection was done in Access 2007 for Windows Vista 
and exported to Excel 2007 for Windows Vista for analyses. 
There were 393 variables including every TR and PR muta-
tions, data on previous ART, and demographic data.
Statistical analysis
Statistical analyses were performed with STATA 8.2 for 
Windows (Statacorp, Texas). We studied the association 
between mutations and HIV-1 Subtypes B, C, and F by 
χ2 test. The significance level of 0.05 and a confidence 
interval (CI) of 95% were used.
Demographic and clinical data from patients (age, 
gender) were compiled for each subtype (B, C, F, and 
mosaics) group and differences were analyzed. Sequenc-
es were analysed according to their assigned HIV-1 
subtype and according to type of ARV exposure, nucle-
oside/nucleotide RT, non-nucleoside RT, or protease in-
hibitors (NRTI, NNRTI, and PI, respectively). Propor-
tions of mutations in viruses within each subtype were 
observed and differences in the proportion of mutations 
were evaluated.
The proportion of patients on different highly active 
antiretroviral therapy (HAART) regimens and those on 
NRTI double therapy prior to HAART were compared 
in different subtypes. The average number of mutations 
and the proportion of resistant strains to NRTI, NNRTI, 
and PI were compared between subtypes.
 
RESULTS
Among genotypes performed from 2003 to 2006, PR 
and RT subtypes have been identified in 389 cases. Most 
patients presented with HIV-1 subtype B and about 
13.11% of patients showed mixed subtypes in PR and 
RT (Table 1).
The average age of patients infected by HIV-1 B, C, F, 
and mosaics was similar, 41.18 (± 6.1); 40.54 (± 6.9); 44.05 
(± 5.9), and 39.76 (± 8.1) years old, respectively. There 
were no significant differences in subtype distribu-
tion throughout the years of study. The prevalence of 
subtypes C and F was significantly higher in women 
(Table 2).
Patients with HIV-1 subtype B were exposed to a 
significantly higher number of ARV (OR 1.09, 95% CI 
1.02-1.16, p 0.0122) and to a higher number of ARV 
regimens (OR 1.14, 95% CI 1.05-1.24, p 0.0013) when 
compared to subtype C. Patients with HIV-1 subtype C 
and F received NRTI double therapy less frequently than 
patients with subtype B and mosaics, but these differ-
ences were not significant (OR 1.47, 95% CI 0.9-1733, 
p 0.327). The duration of exposure to NNRTI was not 
significantly different between subtypes B and the oth-
ers (OR 1.11, 95% CI 0.9-1.74, p 0.178), but subtype C 
virus was significantly less exposed to thymidines (OR 
0.78, 95%CI 0.24-0.95, p 0.037) and PI (OR 0.37, 95%CI 
0.17-0.82, p 0.010) In spite of this more extensive expo-
Toledo, Carvalho, Rossi et al.
232
Table 1. Characterization of the study genotypes by date of collection and subtype prevalence
    Number (n) Frequency (%)
 Date of Genotype Collection
  2003  18 4.63
  2004 102 26.22
  2005 172 44.22
  2006  97 24.94
 HIV-1 Subtype (PR e RT)
  B  239 61.44
  C  80 20.57
  F  19 4.88
  Mosaics or recombinant forms 51 13.11
   B/C 11 17.65
   B/F* 37 72.55
   B/D 1 1.96
   C/F 2  3.92
   B/K 1 1.96
   B/D/F 1 1.96 
PR, protease; RT, reverse transcriptase.
* Two distinct B/F recombinant genomes were identified among the HIV-1 isolates that were grouped as B at PR/F at RT (4/37) 
and F1 or F2 at PR/B at RT (33/37) subtypes.
Table 2. Differences in gender prevalence of HIV-1 subtype
HIV-1 
Subtype                           Female (n = 137)                             Male (n = 252)  OR* 95% IC p  
                
         Number (n)        Frequency (%)            Number (n)      Frequency (%)    
  
Subtype B 58 42.34 181 71.83      
Subtype C 44 32.12 36 14.29 3.81 2.19-6.64 0.0000
Subtype F  10 7.3 9 3.57 3.47 1.32-9.09 0.0070
CRF 25 18.25 26 10.32 3.00 1.58-5.68 0.0004
OR, odds ratio; CI, confidence interval; CRF, circulating recombinant forms.
* Odds ratio comparing each non-B versus B subtypes prevalence between female and male patients.
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sure of subtype B in terms of number of regimen, which 
was characterized by the use of the same NRTI in many 
regimens, there was no difference in terms of type of ex-
posure to ARV between subtypes. Exposure to 3 classes of 
ARV (OR 0.83, 95% CI 0.68-1.0, p 0.0613), exposure to 
PI (OR 1.17, 95% CI 0.9-1.53, p 0.257), and exposure to 
NNRTI (OR 1.13, 95% CI 0.9-1.44, p 0.295) were similar 
between subtype B compared to the others. Exposure to 
IP/r based regimen at the time of genotype testing was 
more frequent in subtype B patients (OR 1.54, 95% CI, 
1.0-2.39, p 0.0048) (Table 3). 
Most of the NRTI, NNRTI, and PI associated mutations 
occurred in all subtype groups (B, C, F, and mosaics). The 
PI mutation 76V was only present in subtype B isolates. 
Subtype F virus did not present the following mutations in 
any sequence analysed: 151-complex (62V, 75I, 77L, 116Y 
and 151M), mutations at codons 101, 106, 179, 188 of RT, 
and mutations 30N, 32I, 50V, 84V, 54MLof PR.
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Table 3. Differences in ARV exposure by HIV-1 subtype
ARV Exposure Subtype B Subtype C Subtype F
Average number of ARVs 6.95* 6.32* 7.12
Average number of regimen 4.34* 3.66* 4.48
Proportion of NRTI double therapy exposure 44.8% 33.8% 36.8%
Average duration of thymidines exposure 74 months 62 months** 73 months
Average duration of NNRTI exposure 10 months 10 months 12.5 months
Average duration of PI exposure 60 months 39.5 months** 65 months
ARV, antiretroviral; NNRTI, non-nucleoside analog reverse transcriptase inhibitors; PI, protease inhibitors.
* Significantly higher number of ARV (OR 1.09, 95% CI 1.02-1.16, p 0.0122) and regimens (OR 1.14, 95% CI 1.05-1.24, p 0.0013) 
was seen in subtype B when compared to subtype C.
** Significant difference in terms of average durations of thymidines (OR 0.78, 95%CI 0.24-0.95, p 0.037) and PI (OR 0.37, 95%CI 
0.17-0.82, p 0.010) exposure was seen in subtype C when compared to subtype B and F.
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Table 4. Differences in median number of PR and RT mutations between HIV-1 subtypes
Number of class  Differences of prevalence OR* 95%IC p
mutation between HIV-1 subtypes 
Number of TAMs  1.16 1.04-1.30 0.0079
Number of NNRTI  Subtype B versus subtypes C,  
related mutations F and CRF 1.23 1.04-1.46 0.0153
Number of MPIM  1.25 1.10-1.41 0.0003
TAMs, Thymidine Analog Mutations; NNRTI, non-nucleoside analog reverse transcriptase inhibitors; MPIM, major PI mutations; 
CRF, circulating recombinant forms; OR, odds ratio; CI, confidence interval.
* Odds ratio calculated comparing the prevalence of mutations and groups of mutations between subtypes.
The average number of TAMs, NNRTI, and PI related mu-
tations was signifi cantly higher in patients harbouring subtype 
B than subtypes C and F (1.44 versus 1.18 and 1.1) (Table 4).
The most frequent NRTI-related mutations in all 
subtypes were M184V and mutations at codons 215, 
41, 67, and 219 of RT. The TAMs at codons 41, 210, and 
215 were signifi cantly less frequent in subtype C (Figure 1). 
TAMs accessory mutations in codons 118 (OR 2.22, 95% CI 
1.29-3.81, p 0.003) and 44 (OR 2.46, 95% CI 1.21-5.01, p 
0.010) were signifi cantly more frequent in subtype B when 
compared to C and F. Mutations at codon 74 (OR 2.16, 95% 
CI 1.03-4.57, p 0.038) of RT and multi NRTI resistance mu-
tations (OR 2.16, 95% CI 1.00-4.73, p 0.048) were also more 
frequent in subtype B than C and F.
The most frequent NNRTI-related mutations in all sub-
types were K103NS, G190AES, and Y181C, with no signifi cant 
difference between them (Figure 2). The NNRTI-related muta-
tion at codon 106 was signifi cantly more prevalent in subtype C 
(OR 9.77, 95% CI 1.04-92.20, p 0.047) than in B and F.
The most frequent major PI mutation was in codons 90, 
82, and 46 in all subtypes. Subtype C virus have a lower preva-
lence of all major PI mutations, except 50L. The mutations at 
codons 32 and 84 and mutation 46I were signifi cantly more 
prevalent in subtype B (Figure 3). The major PI mutation 46L 
was signifi cantly more prevalent in subtype F (OR 7.04, 95% 
CI 2.06-24.07, p 0.018). No differences on prevalence between 
subtypes were seen for mutations D30N and L90M.
Regarding minor PI mutations, the most frequent were 
36IV, 63P, 93L, 71VIT, 54VTAS, 10FIRV, 20MRTI. The muta-
tion 36IV was signifi cantly more frequent in subtypes C (OR 
4.28, 95% CI 2.26-8.10, p 0.000) and F (OR 13.71, 95% CI 
1.76-107.10, p 0.001) when compared to B.
Mutations 20MRT (OR 5.58, 95% CI 1.77-17.62, p 
0.034) and 93L (OR 11.45, 95% CI 5.81-22.57, p 0.000) were 
signifi cantly more prevalent in subtype C when compared 
to B and F.
Mutations 20I (OR 5.67, 95% CI 1.27-25.26, p 0.010), 
60E (OR 2.60, 95% CI 1.10-6.18, p 0.024), 62V (OR 1.97, 
95% CI 1.08-3.58, p 0.024), 63P (OR 5.34, 95% CI 3.30-
8.65, p 0.000), 77I (OR 4.09, 95% CI 1.98-8.45, p 0.00) 
were signifi cantly more prevalent in subtype B when com-
pared to C and F.
234
Figure 3: Prevalence of major PI-related mutations.
The vertical columns represent the frequency of the most 
common major PI mutations (46I, 82ATFSM 90M, 33I, 88DS, 
and 84V) and the mutation 32I in subtypes B (light grey) and 
non-B (dark grey).
The following mutations were significantly more frequent in 
subtype B than non-B: 
*32I (OR 3.52, 95%CI 1.00-12.38, p 0.037); ** 46I (OR 4.39, 
95%CI 2.23-8.61, p 0.0000); *** 84V (OR 2.93, 95%CI 1.17-7.36, 
p 0.0164).
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Figure 1: Prevalence (%) of Thymidine Analog Mutations (TAMs).
The vertical columns represent the frequency of TAMs (41L, 
67N, 70R, 210W, 215YF, 219QE) and the groups of TAMs in 
patients with subtypes B (in light grey) and C (in dark grey).
*Mutation 41L was significantly more frequent in subtype 
B than C (OR 2.27, 95% CI 1.46-3.54, p 0.0002); ** mutation 
210W was significantly more frequent in subtype B than C (OR 
2.31, 95% CI 1.37-3.90, p 0.0013); *** mutations 215YF were 
significantly more frequent in subtype B than C (OR 2.03, 95% 
CI 1.33-3.09, p 0.0008); **** the accumulation of TAMs 41L, 
210W and 215YF was significantly more frequent in subtype 
B than C (OR 1.07, 95% CI 1.0-3.27, p 0.004).
Figure 2: Prevalence of NNRTI-related mutations.
The vertical columns represent proportion of the most 
frequent NNRTI-related mutations (103NS, 190EAS, 181C, and 
188CL) and the 106M mutation in sequences of subtypes B 
(light grey), C (dark grey), and F (white).
* Mutation 106M was significantly more frequent in subtype C 
than in B and F virus (OR 9.77, 95% CI 1.04-92.20, p 0.047).
NNRTI, non-nucleoside analog reverse transcriptase inhibitor.
DISCUSSION
In retrospective and prospective trials all subtypes present 
similar response to HAART,21-25 but the impact of ARV 
treatment on different HIV-1 subtypes and CRFs in Paraná, 
Brazil, is an issue for study. This study enabled estimation 
of drug resistance pattern in HIV subtypes of patients re-
ceiving ART in Paraná, Brazil, from 2003 to 2006. This fi rst 
estimate of the mutations’ prevalence of different subtypes 
in this region shows high frequency of resistance, similar to 
other Brazilian regions, and a peculiar distribution of some 
specifi c subtypes of mutations
The higher prevalence of subtype B sequences, fol-
lowed by subtype C observed is similar to previous Brazilian 
reports,11,13,14 and the higher prevalence of subtypes C and F 
in women is similiar to data reported by Soares et al.11 Fer-
reira et al. also showed a higher prevalence of clade B virus 
(52.6%), followed by clade C (29.8%), mosaics (BC 14%, 
CF 1.8%) and clade F (1.8% in the newly infected patients 
in Curitiba over 2008, but these authors also observed an 
increase in subtype C prevalence in newly infected males,13 
what differ from our sample studied from 2003 to 2006.
Some authors have shown that subtype C was introduced in 
Brazil later than subtype B.9, 11, 12, 26 Because HIV subtype B epi-
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demic is older, it presents the chance of a longer time of treatment 
in patients with this subtype. In fact, patients with subtype B in 
this study had a longer exposure to NRTI and PI but no differ-
ence in prevalence of each subtype from 2003 to 2006 was seen in 
sequences from Paraná. There was no difference in the duration 
of exposure to NNRTI between subtypes, and it can be explained 
by the more recent introduction of this class of ARV.
The overall mutation’s prevalence in PR and RT observed 
in this study is similar in patients HIV-1 from different sub-
types, as reported by many authors.7, 19, 27
The number of NRTI, NNRTI, and major PI mutations 
was signifi cantly higher in subtype B sequences, which can 
be explained by subtype B-infected patients being exposed 
to a signifi cant higher number of regimens and ARVs, while 
the exposure to each ARV class and to NRTI double therapy 
was not signifi cantly different in the subtypes.
The present study showed that NRTI related mutations 
74IV, 41L, 210W, and 215YF were signifi cantly more prev-
alent in subtype B than in subtype C, in accordance with 
previous studies.10, 12, 28, 29 A study by van de Vijver reported 
a higher genetic barrier for acquiring mutation L210W in 
subtype C.30 No difference was seen between NRTI muta-
tions in subtypes B and F as reported by Caride.31
A similar prevalence of NNRTI related mutations be-
tween subtypes was observed according to previous reports,31 
but a signifi cantly higher prevalence of mutation 106M in 
subtype C was seen. The higher acquisition of 106M in RT 
of subtypes C was already reported.32 and this is probably 
facilitated by a polymorphism present in this specifi c sub-
type.33
It was observed a significantly higher prevalence of 
major PI mutations V32I, M46IL, and I84V in HIV-1 sub-
type B in sequences evaluated. Association of I84V and 
subtype B has also been reported by other authors.12, 18, 34, 
35 No difference was seen in Paraná’s sequences in preva-
lence of mutations in PR codons 30 and 90 between sub-
types, while a higher prevalence of changes in PR codon 
90 in non-B subtypes have been reported in some stud-
ies9, 36 and a higher prevalence of changes in codon 30 in 
subtype B in others.12, 35
Minor PI mutation at codon 36 was signifi cantly more 
prevalent in non-B subtypes, according to reports in naïve18, 
34 and treated patients.7, 29, 34 Moreover, mutations L63P and 
V77I were signifi cantly more prevalent in subtype B, as pre-
viously reported.7, 18, 19, 34
Despite the fact that lower accumulation of NRTI and 
major PI mutations in HIV-1 subtype C could be related to 
less exposure to Thymidine and PI, our observations are rel-
evant to confi rm that the HAART available should be extend 
to subtype C in the same way as for the most studied subtype 
B. The same applies to subtype F. Moreover, subtype F virus 
had as much ARV exposure as subtype B and even so did 
not present some mutations in RT (151-complex, mutations 
at codons 101, 106, 179, 188) and in PR (30N, 32I, 50V, 84V, 
54ML), which suggests an overall lower chance of mutation 
acquisition in this subtype.
 
CONCLUSION
In the present study, it was observed a uniform prevalence of 
most mutations among the HIV-1 subtypes. However, it was 
observed a tendency of some NRTI and major PI mutations 
to be more frequent in subtype B. Mutation at codon 106 of 
RT occurred in a higher frequency in subtype C. In addition, 
other signifi cant differences occurred in PR polymorphisms 
in subtypes B, C, and F.
 
ACKNOWLEDGEMENTS
The authors thank Dr. Lilian Amaral Inocêncio, of the Na-
tional STD/AIDS Program, for helping with the approval 
process for the access to the genotypes studied.
 
REFERENCES
1. Hahn BH, Shaw GM, Arya SK, Popovic M, Gallo RC, Wong-
Staal F. Molecular cloning and characterization of the HTLV-
III virus associated with AIDS. Nature 1984; 312(5990):166-9.
2. Robertson DL, Anderson JP, Bradac JA et al. HIV-1 nomencla-
ture proposal. Science 2000; 288(5463):55-6.
3. Robertson DL, Sharp PM, McCutchan FE, Hahn BH. Recom-
bination in HIV-1. Nature 1995; 374(6518):124-6.
4. Blackard JT, Cohen DE, Mayer KH. Human immunodefi cien-
cy virus superinfection and recombination: current state of 
knowledge and potential clinical consequences. Clin Infect Dis 
2002; 34(8):1108-14.
5. Los Alamos National Laboratory. HIV Sequence database. 
[http://www.hiv.lanl.gov/content/sequence/HIV/CRFs/CRFs.
html] 2007.
6. Korber B, Gaschen B, Yusim K, Thakallapally R, Kesmir C, 
Detours V. Evolutionary and immunological implications of 
contemporary HIV-1 variation. Br Med Bull 2001; 58:19-42.
7. Gonzales MJ, Machekano RN, Shafer RW. Human immuno-
defi ciency virus type 1 reverse-transcriptase and protease sub-
types: classifi cation, amino acid mutation patterns, and preva-
lence in a Northern California clinic-based population. J Infect 
Dis 2001; 184(8):998-1006.
8. Wainberg M. HIV-1 subtype distribution and the problem of 
drug resistance. AIDS 2004; 18(Suppl 3):S63-S68.
9. Soares MA, De Oliveira T, Brindeiro RM et al. A specifi c sub-
type C of human immunodefi ciency virus type 1 circulates in 
Brazil. AIDS 2003; 17(1):11-21.
10. Soares EA, Santos RP, Pellegrini JA, Sprinz E, Tanuri A, Soares 
MA. Epidemiologic and molecular characterization of human 
immunodefi ciency virus type 1 in Southern Brazil. J Acquir 
Immune Defi c Syndr 2003; 34(5):520-6.
11. Soares EA, Martínez AM, Souza TM et al. HIV-1 subtype C dis-
semination in southern Brazil. AIDS 2005; 19(Suppl 4):S81-S86.
12. Soares EA, Santos AF, Sousa TM et al. Differential Drug Re-
sistance Acquisition in HIV-1 of Subtypes B and C. PloS One 
2007; 2(8):e730.
Toledo, Carvalho, Rossi et al.
236
13. Ferreira JLP, Thomaz M, Rodrigues R et al. Molecular char-
acterisation of newly identifi ed HIV-1 infections in Curitiba, 
Brazil: preponderance of clade C among males with recent in-
fections. Mem Inst Oswaldo Cruz 2008; 103(8):800-8.
14. Brindeiro RM, Diaz RS, Sabino EC et al. Brazilian Network 
for Drug Resistance Surveillance (HIV-BResNet): a survey of 
chronically infected individuals. AIDS 2003; 17:1063-9.
15 Sabino EC, Shpaer EG, Morgado MG et al. Identifi cation of 
human immunodefi ciency virus type 1 envelope genes recom-
binant between subtypes B and F in two epidemiologically 
linked individuals from Brazil. J Virol 1994; 68(10):6340-6
16. Couto-Fernandez JC, Silva-de-Jesus C, Veloso VG et al. Hu-
man immunodefi ciency virus type 1 (HIV-1) genotyping in 
Rio de Janeiro, Brazil: assessing subtype and drug-resistance 
associated mutations in HIV-1 infected individuals failing 
highly active antiretroviral therapy. Mem Inst Oswaldo Cruz 
2005; 100(1):73-8.
17. de Sa-Filho DJ, Soares MS, Candido V et al. HIV type 1 pol gene 
diversity and antiretroviral drug resistance mutations in Santos, 
Brazil. AIDS Res Hum Retroviruses 2008; 24(3):347-53.
18. Dumans AT, Barreto CC, Santos AF et al. Distinct resistance 
mutation and polymorphism acquisition in HIV-1 protease 
of subtypes B and F1 from children and adult patients under 
virologic failure. Infect Genet Evol 2009; 9(1):62-70.
19. Kantor P, Katzenstein DA, Efron B et al. Impact of HIV-1 sub-
type and antiretroviral therapy on protease and reverse tran-
scriptase genotype: results of a global collaboration. PLoS Med 
2005; 2(4):e112.
20. Johnson A, Brun-Vezinet F, Clotet B et al. Update of the Drug 
Resistance Mutations in HIV-1: Spring 2008. Top HIV Med 
2008; 16(1):62-8.
21. Alexander CS, Montessori B, Dong W et al. Prevalence and re-
sponse to antiretroviral therapy of non-B subtypes of HIV in 
antiretroviral-naive individuals in British Columbia. Antivir 
Ther 2002; 7(1):31-5.
22. Frater AJ, Beardall A, Ariyoshi K et al. Impact of baseline poly-
morphisms in RT and protease on outcome of highly active 
antiretroviral therapy in HIV-1-infected African patients. 
AIDS 2001; 15(12):1493-502.
23. Bocket L, Cheret A, Deuffi c-Burban S et al. Impact of human 
immunodefi ciency virus type 1 subtype on fi rst-line antiretro-
viral therapy effectiveness. Antivir Ther, 2005; 10(2):247-54.
24. Bannister WP, Ruiz L, Loveday C et al. EuroSIDA Study Group. 
HIV-1 subtypes and response to combination antiretroviral 
therapy in Europe. Antivir Ther 2006; 11(6):707-15.
25. Champenois K, Deuffi c-Burban S, Cotte L et al. Natural poly-
morphisms in HIV-1 protease: impact on effectiveness of a 
fi rst-line lopinavir-containing antiretroviral therapy regimen. 
J Med Virol 2008; 80(11):1871-9
26. Salemi M, de Oliveira T, Soares MA, Pybus O, Dumans AT et al. 
Different epidemic potentials of the HIV-1B and C subtypes. J 
Mol Evol, 2005; 60:598-605.
27. Rhee SY, Fessel WJ, Zolopa AR et al. HIV-1 Protease 
and reverse-transcriptase mutations: correlations with 
antiretroviral therapy in subtype B isolates and implica-
tions for drug-resistance surveillance. J Infect Dis 2005; 
192(3):456-65.
28. Dumans AT, Soares MA, Machado ES et al. Synonymous ge-
netic polymorphisms within Brazilian Human Immunodefi -
ciency Virus Type 1 Subtypes may inﬂ uence mutational routes 
to drug resistance. J Infect Dis 2004; 189:1232-8.
29. Cavalcanti AM, Lacerda HR, Brito AM, Pereira S, Medeiros D, 
Oliveira S. Antiretroviral resistance in individuals presenting 
therapeutic failure and subtypes of the human immunodefi -
ciency virus type 1 in the Northeast Region of Brazil. Mem Inst 
Oswaldo Cruz 2007; 102(7):785-92.
30. van de Vijver DA, Wensing AM, Angarano G et al. The calcu-
lated genetic barrier for antiretroviral drug resistance substitu-
tions is largely similar for different HIV-1 subtypes. J Acquir 
Immune Defi c Syndr 2006; 41:352-60.
31. Caride E, Brindeiro R, Hertogs K et al. Drug-resistant reverse 
transcriptase genotyping and phenotyping of B and non-B 
subtypes (F and A) of human immunodefi ciency virus type 
I found in Brazilian patients failing HAART. Virology 2000; 
275:107-15.
32. Grossman Z, Istomin V, Averbuch D et al. Israel AIDS Multi-
Center Study Group. Genetic variation at NNRTI resistance-
associated positions in patients infected with HIV-1 subtype 
C. AIDS 2004; 18(6):909-15.
33. Brenner B, Turner D, Oliveira M et al. A V106M mutation in 
HIV-1 clade C viruses exposed to efavirenz confers crossresist-
ance to non-nucleoside reverse transcriptase inhibitors. AIDS 
2003, 17:F1-F5.
34. Lacerda HR, Medeiros LB, Cavalcanti AM, Ximenes RA, Al-
buquerque MF. Comparison of the epidemiology, profi le of 
mutations, and clinical response to antiretrovirals among sub-
types B and F of the human immunodefi ciency virus type 1. 
Memórias do Instituto Oswaldo Cruz, Rio de Janeiro, v. 102, n. 
6, p. 693-9, 2007.
35. Caride E, Hertogs K, Larder B et al. Genotypic and phenotypic 
evidence of different drug-resistance mutation patterns be-
tween B and non-B subtype isolates of human immunodefi -
ciency virus type 1 found in Brazilian patients failing HAART. 
Virus genes 2001; 23(2):193-202.
36. Grossman Z, Paxinos EE, Averbuch D et al. Mutation D30N is 
not preferentially selected by human immunodefi ciency virus 
type 1 subtype C in the development of resistance to nelfi navir. 
Antimicrob Agents Chemother 2004; 48(6):2159-65.
Genetic diversity of HIV-1 in Paraná, Brazil
